



## Umechrine Cognition to present Phase 2a results at AASLD International Liver Meeting

STOCKHOLM – September 2, 2020. Umechrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company whose novel orally-active GABA<sub>A</sub> receptor modulating steroid antagonist, golexanolone, is in clinical development for hepatic encephalopathy (HE), will present clinical results from its Phase 2a study at The Liver Meeting Digital Experience™ 2020, the premier Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held November 13-16, 2020.

The Liver Meeting® is the premier Annual Meeting in the science and practice of hepatology, including the latest findings on new drugs, novel treatments, and the results from pilot and multicenter studies. The company today announces that the abstract titled "*A Pilot Study of Golexanolone, a Novel GABA-A Receptor Modulating Steroid Antagonist, in Patients With Cirrhosis And Covert Hepatic Encephalopathy (HE)*" has been accepted for presentation at the liver meeting as a Poster of Distinction. Posters of Distinction are classified as being in the top 10% of scored poster abstracts and will receive special recognition.

"We are grateful for this top tier award that will receive special recognition at the liver meeting", said Magnus Doverskog, CEO of Umechrine Cognition. "This study is the first to demonstrate improvement in neuropsychometric performance in patients with cirrhosis through selective inhibition of the synergistic allopregnanolone pathway". "It provides new insight into the pathogenesis of HE and the findings indicate that golexanolone, which could potentially be used alone or in combination with ammonia-lowering agents, merits further development".

**For further information, please contact:**

Magnus Doverskog, CEO, Umechrine Cognition AB

Phone: +46 (0)73 039 20 52, e-mail: [magnus.doverskog@umecrine.se](mailto:magnus.doverskog@umecrine.se)

TO THE EDITORS

**About Umechrine Cognition AB**

Umechrine Cognition, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company, is developing a potential therapy that represents a new target class relevant for several major CNS-related disorders. For more information, please visit [www.umecrinecognition.com](http://www.umecrinecognition.com).